ArticleNitric oxide : biology and chemistry2013
Gaseous nitric oxide reduces influenza infectivity in vitro.
Article in Nitric oxide : biology and chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04337918 (Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- A safety evaluation of intermittent high-dose inhaled nitric oxide in viral pneumonia due to COVID-19: a randomised clinical study.Scientific reports · 2024Trial
- High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure Due to COVID-19: A Multicenter Phase II Trial.American journal of respiratory and critical care medicine · 2023Trial
- Safety and practicality of high dose inhaled nitric oxide in emergency department COVID-19 patients.The American journal of emergency medicine · 2022Trial
- Article
- Penetration and Preliminary Efficacy of a Novel Nitric Oxide-Releasing Gel for Onychomycosis.Journal of fungi (Basel, Switzerland) · 2025Article
- The Potential Role of Nitric Oxide as a Therapeutic Agent against SARS-CoV-2 Infection.International journal of molecular sciences · 2023Review
- The Triple Crown: NO, CO, and HPharmacology & therapeutics · 2023Review
- Clinically Evaluated COVID-19 Drugs with Therapeutic Potential for Biological Warfare Agents.Microorganisms · 2023Review
- Nasal sprays for treating COVID-19: a scientific note.Pharmacological reports : PR · 2023Review
- Gaseous nitric oxide failed to inhibit the replication cycle of SARS-CoV-2 in vitro.Nitric oxide : biology and chemistry · 2023Article
- The Renin-Angiotensin-Aldosterone System, Nitric Oxide, and Hydrogen Sulfide at the Crossroads of Hypertension and COVID-19: Racial Disparities and Outcomes.International journal of molecular sciences · 2022Review
- Utility of NO and HNitric oxide : biology and chemistry · 2022Review
- SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial.The Lancet regional health. Southeast Asia · 2022Article
- High Doses of Inhaled Nitric Oxide as an Innovative Antimicrobial Strategy for Lung Infections.Biomedicines · 2022Review
- NO in Viral Infections: Role and Development of Antiviral Therapies.Molecules (Basel, Switzerland) · 2022Review
- Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19.Current pharmaceutical design · 2022Review
- Antiviral Activity of Nitrosonium Cations against SARS-CoV-2 on a Syrian Hamster Model.Biophysics · 2022Article
- Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.Drug discovery today · 2021Review
- The potential role of inhaled nitric oxide for postexposure chemoprophylaxis of COVID-19.Journal, genetic engineering & biotechnology · 2021Article
- Small-molecule Akt-activation in airway cells induces NO production and reduces IL-8 transcription through Nrf-2.Respiratory research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gaseous nitric oxide (gNO) is an approved vasodilator drug for inhalation up to a maximum dose of 80 ppm. While gNO has been shown, in vitro, to be an effective antibacterial agent (at 160 ppm), NO-donor compounds have been shown to inhibit a variety of viruses at varying stages of replication. This research was done in order to determine whether gNO at 80 or 160 ppm possesses an antiviral effect on influenza viruses. Three strains of influenza (A and B) were exposed to gNO for up to 180 min, before and after infection of MDCK cells. In search for possible mechanism of antiviral action, Neuraminidase (NA) inhibition assay of H1N1 that was exposed to gNO was performed. Results show that when virions were exposed to gNO prior to infection a complete inhibition of infectivity was achieved for all three strains. Post infection exposure of influenza with gNO resulted in about 30% inhibition of infectivity. Further testing showed that when eliminating the pH effect by exposing a dried virus to gNO, 90% inhibition was found after 2h exposure. NA activity, of whole dried H1N1 virus, was found to be inhibited by gNO (80%). These results suggest that 80 and 160 ppm gNO have a time dependent antiviral effect on influenza strains of viruses during various stages of cellular infection, which are not due to concomitant changes in pH in the surrounding milieu. Viral NA inhibition by gNO was shown and may be responsible for this antiviral effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.